Eli Lilly and Company (NYSE: LLY) announces agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. Under the terms of the agreements, Lilly will acquire Curevo and Curevo shareholders could receive up to $1.5 billion in cash, Lilly will acquire LimmaTech for up to $780 million in cash, and Lilly will acquire Vaccine Company and Vaccine Company shareholders could receive up to $1.55 billion in cash.
Read the full article: Lilly Announces Three Acquisitions to Build Infectious Disease Portfolio //
Source: https://www.prnewswire.com/news-releases/lilly-announces-three-acquisitions-to-build-infectious-disease-portfolio-302781404.html